Deucravacitinib + Placebo

Phase 2Active

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Lupus Erythematosus, Discoid

Conditions

Lupus Erythematosus, Discoid, Lupus Erythematosus, Subacute Cutaneous

Trial Timeline

Jul 12, 2021 → Feb 28, 2028

NCT ID

NCT04857034

About Deucravacitinib + Placebo

Deucravacitinib + Placebo is a phase 2 stage product being developed by Bristol Myers Squibb for Lupus Erythematosus, Discoid. The current trial status is active. This product is registered under clinical trial identifier NCT04857034. Target conditions include Lupus Erythematosus, Discoid, Lupus Erythematosus, Subacute Cutaneous.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06532136	Phase 2	Withdrawn	Nov 1, 2024	Jan 1, 2026	Papulopustular Rosacea
NCT05997277	Phase 2	Terminated	Nov 30, 2023	Apr 10, 2025	Hidradenitis Suppurativa
NCT06042920	Approved	Terminated	Oct 9, 2023	Apr 25, 2025	Palmoplantar Psoriasis
NCT04857034	Phase 2	Active	Jul 12, 2021	Feb 28, 2028	Lupus Erythematosus, Discoid

Competing Products

20 competing products in Lupus Erythematosus, Discoid

See all competitors

Product	Company	Stage	Hype Score
Tabalumab Auto-Injector + Tabalumab Prefilled Syringe	Eli Lilly	Phase 3	77
Baricitinib + Placebo	Eli Lilly	Phase 2	52
DS-7011a + Placebo	Daiichi Sankyo	Phase 1	33
DS-7011a + Placebo	Daiichi Sankyo	Phase 1/2	41
tacrolimus	Astellas Pharma	Phase 3	77
Tacrolimus	Astellas Pharma	Pre-clinical	23
tacrolimus capsule + tacrolimus placebo + leflunomide tablet + leflunomide placebo + prednisone	Astellas Pharma	Phase 3	77
tacrolimus	Astellas Pharma	Approved	85
Tacrolimus capsules + Cyclophosphamide injections + Prednisone	Astellas Pharma	Phase 3	77
E6742	Eisai	Phase 1/2	41
Baricitinib + Placebo	Eli Lilly	Phase 3	77
Baricitinib + Placebo	Eli Lilly	Phase 3	77
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of Care	Eli Lilly	Phase 3	77
LY3361237 + Placebo	Eli Lilly	Phase 2	52
LY2127399 + Placebo	Eli Lilly	Phase 3	77
LY3361237 + Placebo	Eli Lilly	Phase 1	33
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks	Eli Lilly	Phase 3	77
Baricitinib + Placebo	Eli Lilly	Phase 3	77
LY3471851 + Placebo	Eli Lilly	Phase 1	33
LY3471851 + Placebo	Eli Lilly	Phase 2	52

Other Products from Bristol Myers Squibb

DeucravacitinibApproved

Aripiprazole + Olanzapine + HaloperidolApproved

Irbesartan + CiprofibrateApproved

Entecavir + Lamivudine Placebo + Lamivudine + Entecavir PlaceboApproved

deucravacitinibApproved